<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16243">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00056498</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH045074</org_study_id>
    <secondary_id>R01MH045074</secondary_id>
    <secondary_id>DSIR 83-ATAP</secondary_id>
    <nct_id>NCT00056498</nct_id>
  </id_info>
  <brief_title>Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine</brief_title>
  <official_title>Clozapine Treatment of Schizophrenic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ortho-McNeil Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether adding the drug risperidone (RisperdalÂ®) is more effective
      than placebo in treating schizophrenic patients who are taking the drug clozapine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clozapine is the only antipsychotic drug that has been approved for treatment resistant
      patients with schizophrenia. However, up to 50% of patients treated with clozapine fail to
      respond and continue to exhibit clinically significant residual positive and negative
      symptoms and cognitive impairments. An emerging trend in treatment is the addition of a
      second antipsychotic drug. This study will determine if risperidone when given as adjunctive
      treatment is more effective than placebo in treating schizophrenic patients failing
      clozapine therapy.

      Participants are randomly assigned to add either adjunctive risperidone or placebo to their
      current clozapine treatment in a single, daily dose for 16 weeks. Positive and negative
      symptoms, cognitive impairments, side effects of the treatment, anxiety, depression,
      hostility symptoms, and quality of life are assessed. Neurological tests, self administered
      questionnaires, and interviews are used to assess patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2001</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Brief Psychiatric Rating Scale (BPRS)</measure>
    <time_frame>Measured at baseline and every 2 weeks for 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Scale assesses psychotic symptoms on a 20-item scale. The severity of each item is rated on a continuous scale from 1-7, with 1 being the least severe and 7 being most severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Testing</measure>
    <time_frame>Measured at baseline and Week 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants assigned to risperidone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants assigned to placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule daily for 16 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperdal</intervention_name>
    <description>Risperdal 4 mg per day for 16 weeks</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Risperidone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV criteria for schizophrenia or schizoaffective disorder

          -  Current clozapine treatment

          -  Moderate illness severity and inadequate positive symptom response to clozapine
             treatment

          -  6 month period of clozapine treatment with documented clozapine blood level greater
             than or equal to 350 ng/ml or clozapine and norclozapine blood level greater than or
             equal to 450 ng/ml

        Exclusion Criteria:

          -  Organic brain disorder

          -  Mental retardation

          -  Medical condition whose pathology or treatment could alter the presentation or
             treatment of schizophrenia or significantly increase the risk associated with the
             proposed treatment protocol

          -  Pregnancy

          -  DSM-IV criteria for current alcohol or substance dependence within the last 6 months
             or DSM-IV criteria for alcohol or substance abuse within the last month

          -  Previously received adjunctive risperidone (at doses greater than or equal to 8
             mg/day) with their clozapine treatment for greater than or equal to 6 weeks
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert W Buchanan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maryland Psychiatric Research Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <lastchanged_date>April 10, 2015</lastchanged_date>
  <firstreceived_date>March 14, 2003</firstreceived_date>
  <firstreceived_results_date>March 23, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Mental Health (NIMH)</investigator_affiliation>
    <investigator_full_name>Robert W. Buchanan</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Though funding was in place beginning in 2001, recruitment took place from 2003 to 2008. Subjects were recruited from the Maryland Psychiatric Research Center Outpatient Reseach clinic, the Treatment Research Program, and community mental health centers.</recruitment_details>
      <pre_assignment_details>86 Participants signed informed consent. 15 were ineligible or excluded. 71 Participants entered the evaluation phase. Two were withdrawn prior to randomization. Four people withdrew after randomization but prior to starting study medications.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Risperidone</title>
          <description>Participants assigned to risperidone</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants assigned to placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Risperidone</title>
          <description>Participants assigned to risperidone</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants assigned to placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="65"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="65.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="48.3" spread="7.2"/>
                <measurement group_id="B2" value="44.1" spread="9.3"/>
                <measurement group_id="B3" value="46.1" spread="8.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="21.0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="44.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="65.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Brief Psychiatric Rating Scale (BPRS)</title>
        <description>Scale assesses psychotic symptoms on a 20-item scale. The severity of each item is rated on a continuous scale from 1-7, with 1 being the least severe and 7 being most severe.</description>
        <time_frame>Measured at baseline and every 2 weeks for 16 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>64 participants began study medication and were used in the Intent to Treat(ITT) analyses (risperidone: 30; placebo:34). 53 subjects were used in the completer analyses (risperidone: 25; placebo: 28) BPRS items 4, 11, 12, and 15 (positive symptoms of schizophrenia), potentially ranging from 4 to 28 were used in the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Risperidone</title>
            <description>Participants assigned to risperidone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants assigned to placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Brief Psychiatric Rating Scale (BPRS)</title>
            <description>Scale assesses psychotic symptoms on a 20-item scale. The severity of each item is rated on a continuous scale from 1-7, with 1 being the least severe and 7 being most severe.</description>
            <units>Units on Scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13.2" spread="3.5"/>
                  <measurement group_id="O2" value="14.1" spread="4.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The GEE method (Liang and Zeger, 1986) was used to compare groups on the proportion of patients who met pre-defined response criterion on psychotic symptoms at the final 4 study assessments (weeks 10,12,14 and 16).
The mixed model or unbalanced repeated measures ANCOVA was used to compare groups on secondary measures. A follow-up completer analysis was used to further evaluate BPRS total and positive symptom item score group differences.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Testing</title>
        <time_frame>Measured at baseline and Week 16</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>08/2015</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Risperidone</title>
          <description>Participants assigned to risperidone</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants assigned to placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal symptoms</sub_title>
                <description>Subject c/o of diarrhea, nausea, and vomiting with a history of constipation and admitted to the hospital. Subject was treated for renal failure secondary to nausea and vomiting. Considered to be severe and possibly drug related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>increased auditory hallucinations</sub_title>
                <description>Participant was hospitalized due to an increase in intensity of auditory hallucinations including commands to harm self and need for hospitalization. Considered to be moderate in severity, and remotely study drug and concomitant drug related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <description>Subject reported to the ER c/o racing pulse and thoughts and experiencing a âpanic attackâ. After overnight observation, patient reports symptoms subsided and all labwork was normal. Determined to be severe and remotely study drug related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert W. Buchanan, MD</name_or_title>
      <organization>Maryland Psychiatric Research Center</organization>
      <phone>410-402-7876</phone>
      <email>rwbuchanan@mprc.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
